Contractors passing the gateway criteria will receive a payment if they meet one or more of the quality criteria bundles/standalone criteria listed in the tables below. Some of the quality criteria are bound together in composite bundles; contractors will need to achieve all activities within a bundle to receive payment for the bundle. Each bundle/standalone criteria is designated a number of points (the number of points has not yet been finalised, PSNC will alert contractors when this information is available).
Risk management and safety composite bundle
|1.||80% of all pharmacy professionals to have completed the CPPE Risk Management training and assessment.|
|2.||80% of all pharmacy professionals to complete CPPE sepsis online training and assessment. Apply learning to respond in a safe and appropriate way when it is suspected that someone has sepsis. Disseminate alert symptoms to staff, to ensure referral to pharmacist.|
The pharmacy has available, at premises level, an update of the previous risk review that the pharmacy team at the premises had drawn up for a risk in that pharmacy. This update must include a recorded reflection on the identified risk and the risk minimisation actions that the pharmacy team has been taking and any subsequent changes identified as a result of the reflection. The risk review should include the risk of missing sepsis identification as a new risk as part of the review, record demonstrable risk minimisation actions that have been undertaken to mitigate the risk.
Note: Pharmacies that did not claim for the risk management quality criterion previously and wish to claim at the next review point must have two identified risks, including the risk of missing sepsis as above, as part of completion and claiming for this whole composite bundle.
|4.||80% of all pharmacy professionals to complete CPPE Reducing look-alike, sound a-like errors (LASA) e-learning and assessment.|
|5.||A new written safety report (and subsequent actions completed in line with current criterion) at premises level available for inspection at review point, covering analysis of incidents and incident patterns (taken from an ongoing log), incorporating learnings from CPPE LASA e-learning. This should include a review of and subsequent actions where mitigation taken has failed to prevent a LASA incident from occurring, evidence of sharing learning locally and nationally, and actions taken in response to national patient safety alerts. Demonstrable evidence of actions identified in the patient safety report have been implemented.|
Medicines safety audits complementing QOF QI bundle
Lithium audit aligned with requirements of the NPSA alert on Lithium.
All patients prescribed lithium:
If the pharmacy has no patients prescribed lithium, complete a safety audit of patients prescribed phenobarbital, methotrexate or amiodarone as alternatives, in line with the QOF QI.
|7.||Valproate safety audit: An audit of the provision of advice on pregnancy prevention for girls and women of childbearing potential taking valproate:
Note: Pharmacies that did not claim for the NSAID audit quality criterion previously and wish to claim at the next review point as part of completion and claiming for this whole composite bundle must complete the audit for the first time and complete the other elements as described above.
Submission of information to NHS England should be reported on the MYS application as part of all above audits.
Prevention composite bundle
|9.||The pharmacy is a Healthy Living Pharmacy level 1 (self-assessment).|
|10.||All patient-facing staff are Dementia Friends.|
|11.||The pharmacy has completed a specified dementia-friendly environment checklist and created an action plan which includes making some demonstrable recorded changes to the environment in line with the checklist, as appropriate.|
|12.||Check all patients with diabetes who present from 1 October 2019 to 31 Jan 2020 have had annual foot and eye checks (retinopathy) – please note, eye checks are only for patients with diabetes aged 12 or over. Make a record on the PMR or appropriate form/patient record and signpost/refer as appropriate. The total number of patients who have had this intervention, the number that have not had one or either check in the last 12 months and where they have been appropriately signposted/referred should be recorded and reported as part of this criterion.|
|13.||The sales by the pharmacy of Sugar Sweetened Beverages (SSB) account for no more than 10% by volume in litres of all beverages sold. The pharmacy must have either achieved this by the review point or declare that they will be meeting this by 31 March 2020.|
Primary Care Networks bundle
|14.||Demonstrate that pharmacies in a PCN area have agreed a collaborative approach to engaging with their PCN, including agreement on a single channel of communication, e.g. by appointing a lead representative for all community pharmacies in the PCN footprint to engage in discussions with the PCN.|
|15.||The pharmacy can show evidence that asthma patients, for whom more than 6 short-acting bronchodilator inhalers were dispensed without any corticosteroid inhaler within a 6 month period, have since the last review point been referred to an appropriate health care professional for an asthma review; and can evidence that they have ensured that all children aged 5-15 prescribed an inhaled corticosteroid for asthma have a spacer device where appropriate in line with NICE TA38 and have a personalised asthma action plan. Refer to an appropriate healthcare professional where this is not the case.|
Digital enablers bundle
|16.||NHS 111 DoS profile – Update the pharmacy’s NHS 111 DoS profile via DoS updater, including opening hours for Bank Holidays, and promptly update as information changes, to ensure information is accurate for the public.|
|17.||Demonstrable access to SCR.|